5 Drug Hopefuls That Are Going to Change Your Life: Part 1 Motley Fool It currently has a partnership with Abbott Labs (NYSE: ABT ) and is in the middle of a late-stage MS trial for daclizumab, a subcutaneous injection for relapsing and remitting MS . More directly related to BG-12, Biogen is exploring its combination ... |
